This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Precision Medicine Conference" (IPMC 2023) scheduled during April 24-26, 2023 in Orlando, Florida, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at precision-medicine@magnusconference.com or call + 1 (702) 988 2320.
Genome editing is a technique for altering the DNA of a wide range of organisms, including plants, bacteria, and animals. To achieve so, scientists employ a variety of technologies. Genome editing tools allow scientists to alter DNA, resulting in changes in physical characteristics such as eye color and illness risk.
The genome of all symbiotic and harmful bacteria living in and on all vertebrates is referred to as the microbiome. Microbiota boost immunity, break down potentially harmful food molecules, and create vitamins and amino acids. Environment, Microbiome, and Host are the three main topics of microbiome study.
Neoantigens are newly produced antigens that the immune system has not previously identified. Neoantigens can be produced from altered tumor proteins or viral proteins as a result of tumour mutations. Because neoantigens are not found in normal tissues, they are highly immunogenic.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Leveraging blockchain technology, edge computing and federated learning to enhance outcomes in precision medicine
Ingrid Vasiliu Feltes, MEDNAX, United States
Title : The new horizons in the patient- centered care for understanding of the reasons of its health problems – Psychosynthesis approach
Ewa Danuta Bialek, Institute of Psychosynthesis, Poland
Title : Hegazy theory for interpretation of human parthenogenesis: A new hypothesis
Abdelmonem Awad Hegazy, Zagazig University, Egypt
Title : Precision Oncology and Personalised Medicine: Innovative Technology for the Treatment of Colorectal Cancer
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : The role of CD44v6 as a new immunotherapy target for urothelial cancer
Iris Adriana Maria Lodewijk, Institute of Biomedical Research, Spain